A review of erythromycin-induced malignant tachyarrhythmia -Torsade de pointes - A case report

Angiology

Volumn 48, Issue 9, 1997, Pages 821-826

  Katapadi, K ^a   Kostandy, G ^a   Katapadi, M ^a   Hussain, K M A ^a   Schifter, D ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CASE REPORT; DRUG INDUCED DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG QT SYNDROME; PNEUMONIA; TORSADE DES POINTES;

EID: 0030773405     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979704800909     Document Type: Article

References (31)

1. Wong CB, Windle J: Erythromycin induced torsade de pointes. Nebr Med J 80:285-286, 1995.
2. McComb JM, Campbell NPS, Cleland J: Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 54:922-923, 1984.
3. Dessertenne F: La tachycardie ventricularie a deux foyers opposes variables. Arch Mal Coeur 59:263-272, 1966.
4. Kossman CE: Torsade de pointes: An addition to the nosography of ventricular tachycardia. Am J Cardiol 42:1054-1058, 1978.
5. Somberg J, Tepper D, Wynn J: QT prolongation. Am Heart J 109:395-398, 1985.
6. Vukmir RB: Torsade de pointes: A review. Am J Emerg Med 3:250-255, 1991.
7. Tzivoni D, Banai S, Schuger C, et al: Treatment of torsade de pointes with magnesium sulfate. Circulation 77:392-397, 1988.
8. Tzivoni D, Keren A, Cohen AM, et al: Magnesium therapy for torsade de pointes. Am J Cardiol 53:528-530, 1984.
9. Orban Z, MacDonald LL, Peters MA, et al: Erythromycin-induced cardiac toxicity. Am J Cardiol 75:859-861, 1995.
10. Moss AJ, Schwartz PJ, Carmpton RS, et al: Long QT syndrome: Prospective longitudinal study of 328 families. Circulation 84:1136-1144, 1991.
11. Freedman RA, Andreson KP, Green LS, et al: Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 59:168-169, 1987.
12. Moss AL, McDonald J: Unilateral cerviothoracic sympathetic ganglionectomy for treatment of long QT interval syndrome. N Engl J Med 285:903-904, 1971.
13. Nattel S, Ranger S, Talajic M, et al: Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysilogical mechanism. Am J Med 89:235-238, 1990.
14. Regan TJ, Khan MI, Oldewurtel HA, et al: Antibiotic effect on myocardial k+ transport and production of ventricular tachycardia (abstract) J Clin Invest 48:68a, 1969.
15. Kadish AH, Moraday F: Torsade de pointes. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology, from Cell to Bed Side. Philadelphia: W.B. Saunders Co, 1990, p 608.
16. Tan HL, Hou CJ, Lauer MR, et al: Electrophysiological mechanisms of the long QT interval syndromes and torsade de pointes. Ann Int Med 122:701-714, 1995.
17. Austin KL, Mather LE, Philopt CR, et al: Intersubject and distribution variability after intravenous administration of erythromycin. Br J Cardiol 10:273-279, 1980.
18. Nilsen OG: Comparative pharmacokinetics of macrolides. J Am Mother 20:81-88, 1987.
19. Kroboth PD, Brown A, Lyon JA, et al: Pharmacokinietics of single dose erythromycin in normal and alcoholic liver disease subjects. Antimicrob Agents Chemother 21:135-140, 1982.
20. Guleon D, Bedock B, Chartier CH, et al: QT prolongation and recurrent "torsade de pointes" during erythromycin lactobionate infusion. Am J Cardiol 58:666, 1986.
21. Oberg KC, Bauman JL: QT interval prolongation and torsade de pointes due to erythromycin lactobionate. Pharmacotherapy 15:687-692, 1995.
22. Rezkalla MA, Pochop C: Erythromycin induced torsade de pointes; case report and review of the literature. S D J Med 5:161-164, 1994.
23. Schoenenberger RA, Haefeli WE, Weiss P, et al: Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsade de pointes) Br Med J 300:1375-1376, 1990.
24. Napolitano C, Silvia G, Priori SG, et al: Torsade de pointes. Mechanisms and management. Drugs 47:51-65, 1994.
25. Geugniaud PY, Guerin C, Mahul P, et al: Torsade de pointes induites par L'association lidocaine-erythromycin et insuffisance hepatique. Presse Med 14: 896, 1985.
26. Gitler B, Berger L, Buffa S: Torsade de pointes induced by erythromycin. Chest 105:368-372, 1994.
27. J. De Koning, van Der Hoeven H, Hamer B, Thompson J: Erythromycin-induced torsade de points and ventricular fibrillation in a patient with Legionella pneumonia. Netherlands J Med 44:131-135, 1994.
28. Wilt JT, Minnema AM, Johnson RF, Rosenblum AM: Torsade de pointes associated with the use of intravenous haloperidol. Ann Int Med 119:391-394, 1993.
29. Cohn JN: Symposium on bepridil, a new antiangial agent. Am J Cardiol 55:1C, 1985.
30. Ponsonnaille J, Citron B, Richard A, et al: An electrophysiological study of the arrhythmogenic effects of erythromycin. Arch Mal Ceour 81:1001-1008, 1988.
31. Herings RM, et al: Torsade de pointes and the use of terfenadine and astemizone in the Netherlands. Pharm World Sci 15:212-218, 1993.